Search research articles
Contact Us
Filters
Showing results (161-170 of 175) with videos related to
Page
of 18
Sort By:
American Journal of Hematology
|
December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Blood Advances
|
January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Krish Patel, Julie M Vose, Sunita D Nasta, et al.
The New England Journal of Medicine
|
February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
Eric Wang, Xiaoli Mi, Meghan C Thompson, et al.
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Leukemia
|
June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P Steensma, Martin Wermke, Virginia M Klimek, et al.
Blood Advances
|
June 23, 2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, et al.
Blood Advances
|
May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Anthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 175) with videos related to
Sort By:
Page
of 18
American Journal of Hematology
|
December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Blood Advances
|
January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Krish Patel, Julie M Vose, Sunita D Nasta, et al.
The New England Journal of Medicine
|
February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
Eric Wang, Xiaoli Mi, Meghan C Thompson, et al.
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Leukemia
|
June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P Steensma, Martin Wermke, Virginia M Klimek, et al.
Blood Advances
|
June 23, 2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, et al.
Blood Advances
|
May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Anthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Page
of 18